Cogent Biosciences, Inc. announced the closing of an upsized underwritten public offering, raising approximately $230 million. The offering included 25,555,556 shares of common stock at $9.00 per share. The net proceeds will be used for development, regulatory activities, and commercial preparations for bezuclastinib and other product candidates. J.P. Morgan, Leerink Partners, and Guggenheim Securities acted as joint book-running managers for the offering. The shares were offered pursuant to an automatic shelf registration statement and may be obtained from the SEC’s website. Cogent Biosciences is focused on developing precision therapies for genetically defined diseases.

Read more at GlobeNewswire: Cogent Biosciences Announces Closing of Upsized Public